Business Wire

CA-SYNACK

28.5.2019 07:50:07 CEST | Business Wire | Press release

Share
Synack Recognized as CREST Accredited Crowdsourced Penetration Testing Company

Synack, the most trusted Crowdsourced Penetration Testing company, announced today it is now both CREST Accredited for penetration testing services and a CREST Member company in the USA. This is further recognition of Synack as the market leader in delivering the most effective, efficient penetration test.

CREST is a not-for-profit accreditation and certification body that represents and supports the technical information security market. CREST was set up in 2006 in response to the clear need for more regulated professional services with known, dependable quality, and is now recognized globally as the cyber assurance body for the technical security industry. CREST has become the respected standard for penetration testing in countries across the world, where it is increasingly a mandatory requirement for companies that have the most stringent security requirements such as government and financial services. Synack has researchers in more than 60 of these countries.

“This accreditation demonstrates that Synack’s crowdsourced penetration testing follows well-established best practices while using software and the world’s best security researchers,” said Dr. Mark Kuhr, Synack CTO and co-founder. “CREST’s accreditation examination determines if an organization meets its risk assessment, technical capability, and code of conduct standards. The CREST organisation clearly understands the challenges enterprises face today in scaling their security practices, and is supporting the G2000 by accrediting Synack to support these challenges. We appreciate the acknowledgement that Synack meets all of those critical requirements.”

Synack has prioritized trust, quality and insights as critical characteristics of a penetration test. The accreditation process determines if an organization meets risk assessment, technical capability, and code of conduct standards. Relative to a traditional penetration test, Synack believes that the crowdsourced approach provides additional testing rigor, enhanced technology, and deeper visibility and control.

“The CREST accreditation provides further recognition of Synack penetration testing, offering the highest levels of technical quality and testing rigor“ said David Charlton, Synack’s Chief Product Strategist and former Head of Penetration Testing at JPMorgan Chase & Co.

Not only does CREST offer an independent, third party assessment of a company’s penetration testing capabilities, it also provides researchers with the opportunity to become CREST qualified researchers. Synack’s crowd includes CREST certified penetration testers. Synack exposes its elite, global security researcher community in 60+ countries to the benefits of CREST. CREST offers a structured entry point for penetration testers globally and could serve as a significant stepping stone to members of the Synack’s Red Team. Synack looks forward to working closely with members of its global community seeking CREST qualifications.

This accreditation is another pillar showing that Synack takes trust seriously. Companies gain intelligence and efficiency by utilizing Synack to address vulnerabilities in a more efficient and effective way while maintaining a strong security posture. Those that work with Synack and use Crowdsourced Penetration Testing for 2+ years are up to 200% more secure than those that do not or have less than a year of usage.

Today, Synack secures >$1 trillion in Fortune 500 revenue, 75% of the top credit card companies, Top 10 consulting firms and security companies, and over 50% of federal cabinet-level agencies. Synack has received awards including 2019 Cyber Defender by CB Insights, CIO Review’s 20 Most Promising Enterprise Security Solution Providers, The Software Report’s Top 25 CyberSecurity Companies, and Wealthfront’s 2019 Career-Launching Companies.

About Synack

Synack, the most trusted crowdsourced security company, delivers comprehensive and continuous penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create a scalable, effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .

Contact:

Ellie McCardwell, Synack Communications Email: press@synack.com

Link:

ClickThru

Social Media:

https://facebook.com/synack

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye